Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Avastin off-licence

- PMLiVE

Bayer’s Xarelto wins another NICE recommendation

Deemed cost-effective use of NHS resources to prevent blood clots following a heart attack

- PMLiVE

Pharma supports first World Thrombosis Day

Aims to raise awareness of the blood clot condition

- PMLiVE

Otmar Wiestler appointed to Bayer supervisory board

He replaces Klaus Kleinfeld

- PMLiVE

Novartis expands eyecare partnership with NHS

And wins new licence for Lucentis

Bayer symbol

Bayer to spin out material science division

German firm will focus solely on life sciences

- PMLiVE

Brain tumour vaccine is UK’s first ‘Promising Innovative Medicine’

Northwest Biotherapeutics’ DCVax-L gets UK version of ‘breakthrough’ status for use in cancer

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

Bayer partners with Glamour on female empowerment

Campaign to support the contraception Skyla

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links